The Meta-Analysis by G P Sonpavde, P Grivas, Y Lin, D Hennessy & J D Hunt, ‘Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials’, which appeared in the July 2021 issue of Future Oncology 17(19), 2545–2558 (2021), was published with an incorrect 95% CI for Anti-PD-1 in table 1. Any-grade irAEs 0.017–0.029 as opposed to the correct 0.189–0.251; Colitis 0.011–0.084 as opposed to the correct 0.017–0.029; Elevated ALT 0.01–0.088 as opposed to the correct 0.011–0.084; Elevated AST 0.064–0.101 as opposed to the correct 0.01–0.088; Hypothyroidism 0.027–0.039 as opposed to the correct 0.064–0.101; Pneumonitis 0.077–0.136 as opposed to the correct 0.027–0.039; Rash 0.049–0.086 as opposed to the correct 0.077–0.136. Grade ≥3 irAEs 0.011–0.021 as opposed to the correct 0.049–0.086; Colitis 0.007–0.043 as opposed to the correct 0.011–0.021; Elevated ALT 0.004–0.055 as opposed to the correct 0.007–0.043; Elevated AST 0.004–0.013 as opposed to the correct 0.004–0.055; Hypothyroidism 0.01–0.02 as opposed to the correct 0.004–0.013; Pneumonitis 0.008–0.03 as opposed to the correct 0.01–0.02; Rash 0.017–0.029 as opposed to the correct 0.008–0.03. In figure 4G the odds ratio (95% CI) for Colitis Any grade was reported as 0.11 as opposed to the correct 0.62. This has now been corrected.
The authors and editors of Future Oncology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.
